Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Metastatic Castration-resistant Prostate Cancer Clinical Trials

5 recruiting trials for Metastatic Castration-resistant Prostate Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
5
Total Trials
5
Recruiting Now
1
Phase 3 Trials
4
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06514521

Post Marketing Study on Pluvicto in Korea

Post marketing study on Pluvicto in Korea

Sponsor: Novartis PharmaceuticalsEnrolling: 2788 locations
RECRUITINGPhase 2NCT06922318

The COSMYC Trial (COmbined Suppression of MYC)

This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size...

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrolling: 501 location
RECRUITINGPhase 1NCT07339267

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

In this study, ASP5541 will be given to Chinese men with prostate cancer. It will be given together with prednisone and androgen deprivation therapy (ADT). Prednisone is a...

Sponsor: Astellas Pharma Global Development, Inc.Enrolling: 121 location
RECRUITINGPhase 1 / Phase 2NCT04104776

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients...

Sponsor: Novartis PharmaceuticalsEnrolling: 27520 locations
RECRUITINGPhase 3NCT06764485

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants...

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant...

Sponsor: CelgeneEnrolling: 96020 locations

Frequently Asked Questions

There are currently 5 clinical trials for Metastatic Castration-resistant Prostate Cancer, with 5 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Metastatic Castration-resistant Prostate Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Metastatic Castration-resistant Prostate Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.